Nanochon
Nanochon specializes in creating treatments that sports medicine doctors use for active patients in need of cartilage restoration. Their product, Chondrograft™, is designed to replace lost or damaged cartilage and stimulate new growth. This is achieved using novel materials combined with 3D-printed designs, making it a cost-effective and straightforward treatment option.
Nanochon
Nanochon specializes in creating treatments that sports medicine doctors use for active patients in need of cartilage restoration. Their product, Chondrograft™, is designed to replace lost or damaged cartilage and stimulate new growth. This is achieved using novel materials combined with 3D-printed designs, making it a cost-effective and straightforward treatment option.
Nanochon™
Rebuilding Your Active Lifestyle
Although surgical devices and techniques for joint replacement have advanced significantly, these standard implants often result in painful recovery for patients, with a prolonged healing process and unlikely full return to active lifestyles. Additionally, these joint replacements typically have a lifespan of about 15 years, making them more suitable for patients over 55. Consequently, younger adults, aged 18 to 55, who suffer from cartilage damage, traumatic injuries, or initial stages of cartilage loss, are left with few treatment options.
Nanochon’s Chondrograft™ device represents a groundbreaking development in medical technology, serving both as an orthopedic load-bearing implant and a tissue growth scaffold. It is engineered to replace lost or damaged cartilage, promoting new growth through the use of cutting-edge nanomaterials and 3-D printing techniques. This innovative approach holds the promise of a more effective, quicker, durable, and cost-efficient solution for treating joint diseases and injuries.
Nanochon's Mission
Nanochon’s mission is to innovate in cartilage replacement and repair, aiming to restore the active lifestyles of countless young patients affected by knee damage without resorting to expensive and invasive temporary solutions.
Established in 2016, the company focuses on minimally invasive early interventions, potentially preventing the necessity of total knee replacements. This approach challenges the current clinical standard of total joint replacement in treating joint diseases.
Technology & Products
Replace & Regrow: Nanochon is dedicated to providing readily available, highly effective solutions that empower sports medicine physicians to assist their patients in resuming their cherished activities. Their Chondrograft™ is designed to restore lost or damaged cartilage, fostering new growth using cutting-edge materials and 3D printing technology.
THE CHONDROGRAFT™: Nanochon’s Chondrograft™ represents a breakthrough in cartilage implant technology skillfully crafted using a synergistic blend of synthetic micro/nanomaterials and advanced 3-D printing techniques. The Chondrograft™ is engineered to effectively engage with the body’s natural stem cells, encouraging them to interact with their new environment positively.
- Synthetic Yet Natural-Like Material: Although synthetic, the material closely emulates the porosity and structure of natural collagen fibers found in cartilage.
- 3-D Printed Structure: The 3-D printing process transforms this material into a highly organized, interconnected structure, enabling Chondrograft™ to seamlessly integrate with the body, absorb blood, and support stem cell attachment post-implantation. Over time, these stem cells work in concert with the implant to regenerate new cartilage.
Importantly, the mechanical strength of Chondrograft™ permits arthroscopic delivery. This feature significantly reduces recovery time and facilitates an expedited return to mobility. As a result, patients benefit from a minimally invasive, durable implant that not only shortens recovery time but also heightens overall patient satisfaction.
Importance in Medical Field
- Chondrograft™ identified as a solution to quickly and permanently repair joint injuries.
- Fills a market gap as there is no current standard treatment for advanced joint injury in adults aged 18 to 55.
- The technology has undergone several validation programs, winning awards and accolades.
- Offers a potential long-lasting, affordable solution to joint disease and injury.
